Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Kidney Diseases, Chronic: later-stage trial registry
2 of 3 indexed Kidney Diseases, Chronic trials are currently recruiting, with more weight in Phase 3-4.
Corpus placement: #5,209 of 28,707 conditions by registered trial count.
3 US clinical trials · 2 currently recruiting · #5,209 of 28,707 conditions by registered trial count
Kidney Diseases, Chronic: 3 US clinical trials tracked, 2 recruiting.
Kidney Diseases, Chronic is the subject of 3 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is Johns Hopkins Bloomberg School of Public Health, running 1 of these trials.
Enrollment posture brief
Registry condition kidney-diseases-chronic
OPEN 2 | RECR 67% | LATE 1 | EARLY 0 | RANK #5209 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Acute Hypoxemic Respiratory Failure (67% recruiting · 6 trials)
Kidney Diseases, Chronic lists 2 open slots (67% of 3 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Kidney Diseases, Chronic on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Kidney Diseases, Chronic is recruiting above its size-band peers.
2 of 3 indexed trials (66.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Open and recent trials
3 total, page 1 of 1
Rutgers University Study of the Genetics of Kidney Disease
Rutgers, The State University of New Jersey
NCT07217535
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
Novartis Pharmaceuticals
NCT06858319
Metabolomics for Identifying Biomarkers of Dietary Intake and Kidney Disease Progression
Johns Hopkins Bloomberg School of Public Health
NCT03202914
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Kidney Diseases, Chronic records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Kidney Diseases, Chronic trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Kidney Diseases, Chronic page
3 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Kidney Diseases, Chronic trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Johns Hopkins Bloomberg School of Public Health sponsors the most Kidney Diseases, Chronic trials on record, review their full trial history before evaluating a specific study. See Johns Hopkins Bloomberg School of Public Health's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Kidney Diseases, Chronic condition card totals 3 registered trials; most-linked intervention Very low protein and phosphorus; top US site state Tennessee. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.